387
edits
Changes
Created page with '{{Drugcombi | base = carbamazepine | add = topiramate | info = * Carbamazepine is principally metabolized by CYP3A4 (also CYP2C8), but is also a potent inducer of CYP1A2, CYP3A4...'
{{Drugcombi
| base = carbamazepine
| add = topiramate
| info =
* Carbamazepine is principally metabolized by CYP3A4 (also CYP2C8), but is also a potent inducer of CYP1A2, CYP3A4 and UDP-glucuronosyltransferases.
* Topiramate induces CYP3A4 and is an inhibiter of CYP2C19.
| start =
* Carbamazepine can increase topiramate clearance. By adding topiramate to carbamazepine no dose adaptation is necessary. <ref name=”bazire”> Bazire S, Pshychotropic Drug Directory 2007, HealthComm UK Limited, Aberdeen, 2007. </ref> <ref name=”medicatiebewaking”> Schalekamp T. et al, Interacties met Psychofarmaca, Stichting Health Base, Houten, 2002. </ref>
| cave =
* This combination of drugs is subject to pharmacokinetic drug interactions. Discontinuation or dose reduction of either drug will need monitoring of the clinical effects and dose adaptation of the drug remained.
}}
| base = carbamazepine
| add = topiramate
| info =
* Carbamazepine is principally metabolized by CYP3A4 (also CYP2C8), but is also a potent inducer of CYP1A2, CYP3A4 and UDP-glucuronosyltransferases.
* Topiramate induces CYP3A4 and is an inhibiter of CYP2C19.
| start =
* Carbamazepine can increase topiramate clearance. By adding topiramate to carbamazepine no dose adaptation is necessary. <ref name=”bazire”> Bazire S, Pshychotropic Drug Directory 2007, HealthComm UK Limited, Aberdeen, 2007. </ref> <ref name=”medicatiebewaking”> Schalekamp T. et al, Interacties met Psychofarmaca, Stichting Health Base, Houten, 2002. </ref>
| cave =
* This combination of drugs is subject to pharmacokinetic drug interactions. Discontinuation or dose reduction of either drug will need monitoring of the clinical effects and dose adaptation of the drug remained.
}}
